Elicio Therapeutics, Inc. (ELTX) Deferred State and Local Income Tax Expense (Benefit)

Elicio Therapeutics, Inc. Deferred State and Local Income Tax Expense (Benefit)

Elicio Therapeutics, Inc. (ELTX) reported Deferred State and Local Income Tax Expense (Benefit) of $1.19 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.

Financial Statements › Expense Statement › Income Tax

us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2025-03-31

• Elicio Therapeutics, Inc. deferred state and local income tax expense (benefit) for fiscal 2024 was $1.19M, a 61.75% decline from fiscal 2023.
• Elicio Therapeutics, Inc. deferred state and local income tax expense (benefit) for fiscal 2023 was $3.12M, a 48.24% increase from fiscal 2022.
• Elicio Therapeutics, Inc. deferred state and local income tax expense (benefit) for fiscal 2022 was $2.10M.
• Elicio Therapeutics, Inc. deferred state and local income tax expense (benefit) for fiscal 2021 was -$4.78M.